SK is a 24 year old female that presents to your clinic with daily asthma symptoms. You diagnose SK with uncontrolled asthma and decide to start asthma therapy per GINA Track 1. What will the prescription include for SK?

Rationale: A. Leukotriene receptor antagonists are considered alternative maintenance therapies rather than preferred first-line options in the GINA guidelines. They target the inflammatory pathway by blocking cysteinyl leukotriene receptors but are generally less effective than inhaled corticosteroids. In Track 1, they do not satisfy the requirement for a combined anti-inflammatory reliever. B. Using a short acting beta agonist (SABA) as a standalone reliever or in combination with as-needed corticosteroids is the foundation of GINA Track 2. While this approach addresses bronchoconstriction, it is not the preferred strategy in Track 1. Track 1 specifically prioritizes formoterol as the reliever to provide rapid onset and anti-inflammatory coverage. C. Anticholinergics or long-acting muscarinic antagonists are typically reserved as add-on therapies for patients with severe, persistent asthma who remain symptomatic on dual therapy. They provide bronchodilation by blocking parasympathetic nerve signals but do not address the primary eosinophilic inflammation. They are not indicated as the initial management strategy for daily asthma symptoms. D. Maintenance and Reliever Therapy (MART) utilizing a low-dose Inhaled Corticosteroid-Formoterol combination is the preferred Step 3 management in GINA Track 1. This regimen provides consistent anti-inflammatory maintenance while allowing the same inhaler to be used for rapid symptom relief. It significantly reduces the risk of severe exacerbations compared to using a SABA reliever.